The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trialYajing Zhu, Theodoros Foukakis, Mattias Bergqvist et al.|Breast Cancer Research and Treatment|2024Cited by 6
Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trialKang Wang, Theodoros Foukakis, Yajing Zhu et al.|Cancer Research|2023Cited by 0